According to Zacks, analysts expect that Coherus Biosciences will report full year earnings of ($5.20) per share for the current financial year, with EPS estimates ranging from ($5.28) to ($5.12). For the next financial year, analysts anticipate that the company will post earnings of ($2.39) per share, with EPS estimates ranging from ($3.31) to ($1.47). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Coherus Biosciences.
Analysts expect Coherus Biosciences Inc (NASDAQ:CHRS) to post earnings of ($1.40) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Coherus Biosciences’ earnings. Coherus Biosciences posted earnings of ($1.72) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 18.6%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, August 8th.
Coherus Biosciences (NASDAQ:CHRS) last released its quarterly earnings data on Monday, May 8th. The biotechnology company reported ($1.54) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.54). The company had revenue of $0.16 million for the quarter. A number of equities analysts recently issued reports on the company. Maxim Group restated a “buy” rating and set a $43.00 price objective on shares of Coherus Biosciences in a report on Monday. BMO Capital Markets restated an “outperform” rating and set a $54.00 price objective on shares of Coherus Biosciences in a report on Monday. Zacks Investment Research cut Coherus Biosciences from a “buy” rating to a “hold” rating in a report on Thursday, February 16th. Credit Suisse Group AG restated a “buy” rating and set a $38.00 price objective on shares of Coherus Biosciences in a report on Friday, April 21st. Finally, Robert W. Baird restated an “outperform” rating and set a $40.00 price objective on shares of Coherus Biosciences in a report on Wednesday, February 1st. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $40.38.
In other Coherus Biosciences news, insider Alan C. Herman sold 11,333 shares of the company’s stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $20.73, for a total value of $234,933.09. Following the completion of the sale, the insider now directly owns 90,452 shares in the company, valued at approximately $1,875,069.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 32.88% of the stock is currently owned by corporate insiders. Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc raised its position in Coherus Biosciences by 15.9% in the first quarter. Legal & General Group Plc now owns 8,295 shares of the biotechnology company’s stock valued at $173,000 after buying an additional 1,137 shares during the last quarter. Endurant Capital Management LP bought a new position in Coherus Biosciences during the third quarter valued at approximately $225,000. BlueCrest Capital Management Ltd bought a new position in Coherus Biosciences during the first quarter valued at approximately $246,000. Wells Fargo & Company MN raised its position in Coherus Biosciences by 11.3% in the third quarter. Wells Fargo & Company MN now owns 13,360 shares of the biotechnology company’s stock valued at $358,000 after buying an additional 1,354 shares during the last quarter. Finally, Tudor Investment Corp Et Al raised its position in Coherus Biosciences by 34.9% in the fourth quarter. Tudor Investment Corp Et Al now owns 14,396 shares of the biotechnology company’s stock valued at $405,000 after buying an additional 3,726 shares during the last quarter. 64.52% of the stock is owned by hedge funds and other institutional investors.
Coherus Biosciences (NASDAQ:CHRS) traded up 0.23% during mid-day trading on Thursday, hitting $22.05. The stock had a trading volume of 228,737 shares. Coherus Biosciences has a 12 month low of $14.00 and a 12 month high of $31.98. The stock’s market cap is $1.13 billion. The stock’s 50-day moving average price is $19.96 and its 200-day moving average price is $24.71. Coherus Biosciences Company Profile
Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.
Get a free copy of the Zacks research report on Coherus Biosciences (CHRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for Coherus Biosciences Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Coherus Biosciences Inc and related companies with our FREE daily email newsletter.
For more information about research offerings from Zacks Investment Research, visit Zacks.com